Barrier Protection Measures for the Management of Allergic Rhinitis: A Systematic Review and Meta-analysis
Authors:
- 16 March 2020
- journal article
- review article
- Published by SAGE Publications in American Journal of Rhinology & Allergy
- Vol. 34 (4) , 564-572
Abstract
Background: Pharmacotherapy for allergic rhinitis (AR) still remains unsatisfying regarding its effect and safety. Barrier protection measures may be a good choice for the patients with AR. Objective: To assess the efficacy and safety of barrier protection measures in the treatment of AR. Methods: We selected relevant randomized controlled trials published between January 1, 1990, and February 20, 2019, by searching Embase, PubMed, Cochrane, Web of Knowledge, and ClinicalTrials.gov. The primary outcome for this analysis was rhinitis symptom scores, overall quality of life, nasal peak inspiratory flow (NPIF), and adverse events. Differences were expressed as weighted mean difference (WMD) with 95% confidence intervals (CIs) for continuous outcomes. Statistical heterogeneity across trials was assessed with the statistic ( P < .1) and the I 2 statistic. Results: Fifteen RCTs (with data for 1154 participants) satisfied our inclusion criteria. The types of barrier protection measures comprised cellulose, pollen blocker cream, microemulsion, and nasal filter. To reduce the potential risk of bias and heterogeneity, we carried out subgroup analysis according to different types of barrier protection measures (cellulose: WMD = –2.18, 95% CI, –3.01 to –1.35, P < .00001; pollen blocker cream: WMD = –4.55, 95% CI, –6.10 to –3.00, P < .00001; microemulsion: WMD = –0.22, 95% CI, –0.42 to –0.03, P = .03). Findings from our meta-analysis show that, compared with placebo, barrier protection measures can yield improved symptomatic control for AR, with no increase in adverse events. Furthermore, barrier protection measures can improve the quality of life and NPIF. Conclusion: Although further studies are still needed, our findings clearly lend support to barrier protection measures as a safe and efficacious option for the treatment of AR patients.Keywords
Funding Information
- Guangdong Province Natural Science Grant (2018A030310325)
- Guangdong Province Medical Science Research Grant (A2017049)
- Zhuhai City Science and Technology Project (20171009E030016)
This publication has 24 references indexed in Scilit:
- Methyl-cellulose powder for prevention and management of nasal symptomsExpert Review of Respiratory Medicine, 2017
- A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults with Grass Pollen Allergy: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group StudyInternational Archives of Allergy and Immunology, 2014
- Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic reviewCurrent Medical Research and Opinion, 2014
- A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study)Allergy, Asthma & Clinical Immunology, 2013
- Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 RevisionJournal of Allergy and Clinical Immunology, 2010
- Seawater gel in allergic rhinitis: entrapment effect and mucociliary clearance compared with salineTherapeutic Advances in Respiratory Disease, 2009
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Use of cellulose powder for the treatment of seasonal allergic rhinitisAdvances in Therapy, 2003
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002